Cellectar Biosciences, Inc.
CLRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | -0.00 | 0.02 |
| FCF Yield | -24.14% | -44.72% | -64.58% | -87.58% |
| EV / EBITDA | -1.27 | -0.14 | -0.17 | 0.81 |
| Quality | ||||
| ROIC | -49.44% | -76.23% | -63.31% | -78.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.94 | 1.42 | 4.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 16.43% | 45.48% | 14.50% | -19.72% |
| Safety | ||||
| Net Debt / EBITDA | 2.76 | 1.77 | 2.12 | 1.80 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,911.67 | 0.00 | 0.00 | 0.00 |